Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment
Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity through the 48 weeks of treatment
Data presented today in a late-breaking oral presentation at AAD VMX 2021
Management to host an investor call today at 12:00 p.m. EDT
BOULDER, Colo., April 23, 2021 (GLOBE NEWSWIRE) Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced results from its Phase 3 open-label, long-term safety study (“ARGYLE” or “LTSS”), which were also presented today in a late-breaking oral presentation at the American Academy of Dermatology’s (“AAD”) 2021 Virtual Meeting Experience (“VMX”). The ARGYLE study assessed the long-term safety and efficacy
Brickell Biotech Reports Results from U S Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.